

ASX ANNOUNCEMENT

Wednesday 18 August 2021

Half Year Results Presentation and Investor Conference Call

Palla Pharma Limited (ASX:PAL) advises that Chairman Simon Moore and Interim Chief Executive Officer Brendan Middleton will host an analyst and investor conference call on Monday, 30 August 2021 at 12:00 midday AEST to present the Company's results for the half year ended 30 June 2021.

An accompanying presentation will be made available via the ASX announcement platform prior to the call.

Conference call details

To pre-register for this conference and avoid a queue when calling, please use the following link below:

https://sl.c-conf.com/diamondpass/10016033-amds444.html

You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

If you are unable to register, then at the time of the conference you can call one of the numbers below and provide the **conference ID 10016033** to an operator:

- Attendee Dial-in (Australia Toll Free): 1800 554 501
- Alternate Australia Toll Free: 1 800 870 653

This announcement has been authorised for release by the Chairman.

For more information please contact:

Simon Moore
Chairman
Palla Pharma Limited
+61 3 9301 0800
Adrian Mulcahy
Investor Relations
Market Eye
+61 438 630 422 or

+61 3 9301 0800 +61 438 630 422 or ir@pallapharma.com

Brendan MiddletonTristan EverettInterim CEOMedia EnquiriesPalla Pharma LimitedMarket Eye

+61 3 9301 0800 +61 403 789 096 or media@pallapharma.com

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.